Clinical Trials Logo

Filter by:
  • Suspended  
  • « Prev · Page [3]
NCT ID: NCT00991744 Suspended - Clinical trials for Acute Lymphoblastic Leukemia

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

Start date: January 2009
Phase: Phase 3
Study type: Interventional

- Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with intrathecal liposomal cytarabine and prednisolone during maintenance therapy will decrease the CNS relapse rate in high-risk ALL patients. - Both acute and long-term toxicity are equal in both treatment arms.

NCT ID: NCT00990444 Suspended - Diabetes Mellitus Clinical Trials

A Two Part Study of Peroral Insulin in Type 2 Diabetes

ORA2
Start date: September 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine. Oral administration with uptake from the lesser intestine would offer major advantages if made possible. It would offer a simple non-injection method to administer insulin in connection with a meal and absorbed insulin would enter the blood stream and mimic the natural distribution in the body with a first pass through the liver. The sponsor of this study has developed a novel oral insulin formulation that is based on a proprietary dextran matrix. The investigational drug is a capsule containing 100 IU of human insulin in dextran matrix. The primary objective of this study is to establish the safety, tolerance and PD profile (i.e. pharmacodynamic parameters for glucose and insulin) of peroral insulin in dextran matrix in patients with type 2 diabetes. The phase I/II study protocol consists of two parts; part 1 (dose finding) and part 2 (dose verification). In study part 1 single escalating doses of oral insulin or placebo is given to the test subjects. Capillary blood glucose is used to assess the insulin effect. Subsequently, in study part 2, the investigational drug will be administered 3 times daily on 6 consecutive days. The starting dose of part 2 will be the lowest effective dose found in study part 1. Dose escalation will be done in increments of 100 IU. The total number of subjects will be 32 (for part 1 and 2 combined).

NCT ID: NCT00180570 Suspended - Bradycardia Clinical Trials

SALT - Success of Active Versus Passive Lead Fixation of Atrial Pacing/Sensing Electrodes

SALT
Start date: January 1997
Phase: Phase 4
Study type: Interventional

Randomised Comparison with regards to complication rate and electrical measurements of atrial leads with different fixation mechnism